CE Symposium- Atherosclerotic Cardiovascular Disease, Heart Failure, and SGLT2 Inhibitors: Implementing Evidence-Based Treatment Strategies

SPRINGFIELD, N.J. - Feb. 28, 2020 - PRLog -- Cardiovascular nurses play a pivotal role in facilitating cardiovascular risk reduction in their patients.  In cardiovascular outcome trials (CVOTs), SGLT2 inhibitors have been demonstrated to reduce the risk for major cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD). In addition, SGLT2 inhibitors prevent heart failure (HF) in patients with ASCVD, and without ASCVD but with multiple cardiovascular risk factors.  HF with comorbid diabetes is associated with particularly poor clinical outcomes, despite the use of well-established, guideline-recommended HF therapies.  Recent evidence from a HF outcome trial has indicated a benefit with SGLT2 inhibition in treating HF both in patients with and without diabetes receiving current standard of care; this benefit emerges early--within 4 weeks after initiation of therapy--and is irrespective of ejection fraction. Consequently, the clinical evidence, combined with changes in clinical practice guidelines and publication of scientific statements from diabetes and cardiovascular associations, has created an urgent need for cardiovascular nurses to be aware of this information, and to utilize SGLT2 inhibitors in their patients.  In this symposium, experts in HF and comorbid diabetes will provide cardiovascular nurses with up-to-date evidence with SGLT2 inhibitors on ASCVD risk reduction, and prevention and treatment of HF.  Tips for cardiovascular nurses on how to use SGLT2 inhibitors safely and effectively will be presented, with a case presentation illustrating best practices and describing supportive evidence.

Register Online

Faculty:
Cindy Lamendola, MSN, ANP-BC, FAHA, FPCNA
Nurse Practitioner and Clinical Research Coordinator
Stanford University School of Medicine

Darren McGuire, MD, MHSc
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). Multiple educational grants have been requested to support this program. PCNA is approved as a provider of nurse practitioner continuing education (CE) programs by the American Association of Nurse Practitioners (AANP), provider number 030602. This program is accredited for 1 contact hour of continuing education. This program was planned in accordance with AANP CE Policies and Commercial Support Standards.

PCNA and Voxmedia International gratefully acknowledge the educational grant provided by AstraZeneca Pharmaceuticals LP.

This educational activity is intended for Cardiovascular Nurse Practitioners, Nurses, and other clinicians attending the 2020 PCNA Annual Meeting.

Pre-registration is for planning purposes only. For additional CME activities and online cme courses visit http://www.CMEPlanet.com